Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Indinavir Sulfate

FDA-approved product (capsule, oral), marketed as Crixivan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Indinavir Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Indinavir Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Indinavir Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs

    NCT00002407

    Registered record
    Registry ID
    NCT00002407
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Nevirapine; Lamivudine; Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Nevirapine; Lamivudine; Stavudine +1 more
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations

    NCT00002430

    Registered record
    Registry ID
    NCT00002430
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Nelfinavir mesylate; Lamivudine; Stavudine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Nelfinavir mesylate; Lamivudine; Stavudine
    PhaseNot applicable
    Registry statusCompleted

  • The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment

    NCT00005118

    Registered record
    Registry ID
    NCT00005118
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Ritonavir
    PhasePhase 2
    Registry statusUnknown

  • A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection

    NCT00006154

    Registered record
    Registry ID
    NCT00006154
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Ritonavir; Abacavir sulfate; Efavirenz; Stavudine; Didanosine; Aldesleukin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Ritonavir; Abacavir sulfate; Efavirenz +3 more
    PhasePhase 3
    Registry statusCompleted

  • Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

    NCT00027339

    Registered record
    Registry ID
    NCT00027339
    Conditions
    HIV Infections
    Interventions
    lopinavir/ritonavir; indinavir sulfate; tenofovir disoproxil fumarate; ritonavir; fosamprenavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2005-06
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionlopinavir/ritonavir; indinavir sulfate; tenofovir disoproxil fumarate; ritonavir +1 more
    PhasePhase 2
    Registry statusCompleted